APO Research
Talk to an analyst

APO RESEARCH · REPORT

Pneumococcal 13-valent Conjugate Vaccine

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Pneumococcal 13-valent Conjugate Vaccine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

28 December 2025173 pages

Choose your research edition.

Industry ResearchPneumococcal 13-valent Conjugate Vaccine Industry Research Report 2026108 pages · $2,950 USDIndustry Growth & TrendsGlobal Pneumococcal 13-valent Conjugate Vaccine Industry Growth and Trends Forecast to 203278 pages · $3,450 USDMarket StructureGlobal Pneumococcal 13-valent Conjugate Vaccine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032173 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Pneumococcal 13-valent Conjugate Vaccine Market Outlook and Growth Opportunities 2026194 pages · $4,250 USDMarket Analysis & ForecastGlobal Pneumococcal 13-valent Conjugate Vaccine Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

The global Pneumococcal 13-valent Conjugate Vaccine market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Pneumococcal 13-valent Conjugate Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Pneumococcal 13-valent Conjugate Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Pneumococcal 13-valent Conjugate Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Pneumococcal 13-valent Conjugate Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Pneumococcal 13-valent Conjugate Vaccine include Pfizer, BIOKANGTAI and Walvax, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Pneumococcal 13-valent Conjugate Vaccine market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Pneumococcal 13-valent Conjugate Vaccine and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Pneumococcal 13-valent Conjugate Vaccine sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Pneumococcal 13-valent Conjugate Vaccine market size, projected growth trends, production technologies, key applications, and end-use industries.

Pneumococcal 13-valent Conjugate Vaccine Segment by Company

Pfizer

BIOKANGTAI

Walvax

Pneumococcal 13-valent Conjugate Vaccine Segment by Type

0.5ml

Other

Pneumococcal 13-valent Conjugate Vaccine Segment by Application

Hospital

Clinic

Pneumococcal 13-valent Conjugate Vaccine Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Pneumococcal 13-valent Conjugate Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Pneumococcal 13-valent Conjugate Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Pneumococcal 13-valent Conjugate Vaccine.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Pneumococcal 13-valent Conjugate Vaccine market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Pneumococcal 13-valent Conjugate Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Pneumococcal 13-valent Conjugate Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Pneumococcal 13-valent Conjugate Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Pneumococcal 13-valent Conjugate Vaccine Industry Trends Table 2. Pneumococcal 13-valent Conjugate Vaccine Industry Drivers Table 3. Pneumococcal 13-valent Conjugate Vaccine Industry Opportunities and Challenges Table 4. Pneumococcal 13-valent Conjugate Vaccine Industry Restraints Table 5. Global Pneumococcal 13-valent Conjugate Vaccine Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Pneumococcal 13-valent Conjugate Vaccine Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Pneumococcal 13-valent Conjugate Vaccine Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global Pneumococcal 13-valent Conjugate Vaccine Sales Market Share by Manufacturers Table 9. Global Pneumococcal 13-valent Conjugate Vaccine Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Pneumococcal 13-valent Conjugate Vaccine Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Pneumococcal 13-valent Conjugate Vaccine Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Pneumococcal 13-valent Conjugate Vaccine Manufacturers, Product Type & Application Table 13. Global Pneumococcal 13-valent Conjugate Vaccine Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Pneumococcal 13-valent Conjugate Vaccine by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of 0.5ml Table 17. Major Manufacturers of Other Table 18. Global Pneumococcal 13-valent Conjugate Vaccine Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 19. Global Pneumococcal 13-valent Conjugate Vaccine Sales by Type (2021-2026) & (K Units) Table 20. Global Pneumococcal 13-valent Conjugate Vaccine Sales by Type (2027-2032) & (K Units) Table 21. Global Pneumococcal 13-valent Conjugate Vaccine Sales Market Share by Type (2021-2026) Table 22. Global Pneumococcal 13-valent Conjugate Vaccine Sales Market Share by Type (2027-2032) Table 23. Global Pneumococcal 13-valent Conjugate Vaccine Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 24. Global Pneumococcal 13-valent Conjugate Vaccine Revenue by Type (2021-2026) & (K Units) Table 25. Global Pneumococcal 13-valent Conjugate Vaccine Revenue by Type (2027-2032) & (K Units) Table 26. Global Pneumococcal 13-valent Conjugate Vaccine Revenue Market Share by Type (2021-2026) Table 27. Global Pneumococcal 13-valent Conjugate Vaccine Revenue Market Share by Type (2027-2032) Table 28. Major Manufacturers of Hospital Table 29. Major Manufacturers of Clinic Table 30. Global Pneumococcal 13-valent Conjugate Vaccine Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 31. Global Pneumococcal 13-valent Conjugate Vaccine Sales by Application (2021-2026) & (K Units) Table 32. Global Pneumococcal 13-valent Conjugate Vaccine Sales by Application (2027-2032) & (K Units) Table 33. Global Pneumococcal 13-valent Conjugate Vaccine Sales Market Share by Application (2021-2026) Table 34. Global Pneumococcal 13-valent Conjugate Vaccine Sales Market Share by Application (2027-2032) Table 35. Global Pneumococcal 13-valent Conjugate Vaccine Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 36. Global Pneumococcal 13-valent Conjugate Vaccine Revenue by Application (2021-2026) & (K Units) Table 37. Global Pneumococcal 13-valent Conjugate Vaccine Revenue by Application (2027-2032) & (K Units) Table 38. Global Pneumococcal 13-valent Conjugate Vaccine Revenue Market Share by Application (2021-2026) Table 39. Global Pneumococcal 13-valent Conjugate Vaccine Revenue Market Share by Application (2027-2032) Table 40. Global Pneumococcal 13-valent Conjugate Vaccine Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 41. Global Pneumococcal 13-valent Conjugate Vaccine Sales by Region (2021-2026) & (K Units) Table 42. Global Pneumococcal 13-valent Conjugate Vaccine Sales Market Share by Region (2021-2026) Table 43. Global Pneumococcal 13-valent Conjugate Vaccine Sales Forecasted by Region (2027-2032) & (K Units) Table 44. Global Pneumococcal 13-valent Conjugate Vaccine Sales Forecasted Market Share by Region (2027-2032) Table 45. North America Pneumococcal 13-valent Conjugate Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 46. North America Pneumococcal 13-valent Conjugate Vaccine Sales by Country (2021-2026) & (K Units) Table 47. North America Pneumococcal 13-valent Conjugate Vaccine Sales by Country (2027-2032) & (K Units) Table 48. Europe Pneumococcal 13-valent Conjugate Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 49. Europe Pneumococcal 13-valent Conjugate Vaccine Sales by Country (2021-2026) & (K Units) Table 50. Europe Pneumococcal 13-valent Conjugate Vaccine Sales by Country (2027-2032) & (K Units) Table 51. Asia Pacific Pneumococcal 13-valent Conjugate Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 52. Asia Pacific Pneumococcal 13-valent Conjugate Vaccine Sales by Country (2021-2026) & (K Units) Table 53. Asia Pacific Pneumococcal 13-valent Conjugate Vaccine Sales by Country (2027-2032) & (K Units) Table 54. South America, Middle East and Africa Pneumococcal 13-valent Conjugate Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 55. South America, Middle East and Africa Pneumococcal 13-valent Conjugate Vaccine Sales by Country (2021-2026) & (K Units) Table 56. South America, Middle East and Africa Pneumococcal 13-valent Conjugate Vaccine Sales by Country (2027-2032) & (K Units) Table 57. Global Pneumococcal 13-valent Conjugate Vaccine Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 58. Global Pneumococcal 13-valent Conjugate Vaccine Revenue by Region (2021-2026) & (US$ Million) Table 59. Global Pneumococcal 13-valent Conjugate Vaccine Revenue by Region (2027-2032) & (US$ Million) Table 60. Global Pneumococcal 13-valent Conjugate Vaccine Revenue Market Share by Region (2021-2026) Table 61. Global Pneumococcal 13-valent Conjugate Vaccine Revenue Market Share by Region (2027-2032) Table 62. Pfizer Company Information Table 63. Pfizer Business Overview Table 64. Pfizer Pneumococcal 13-valent Conjugate Vaccine Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 65. Pfizer Pneumococcal 13-valent Conjugate Vaccine Product Portfolio Table 66. Pfizer Recent Development Table 67. BIOKANGTAI Company Information Table 68. BIOKANGTAI Business Overview Table 69. BIOKANGTAI Pneumococcal 13-valent Conjugate Vaccine Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 70. BIOKANGTAI Pneumococcal 13-valent Conjugate Vaccine Product Portfolio Table 71. BIOKANGTAI Recent Development Table 72. Walvax Company Information Table 73. Walvax Business Overview Table 74. Walvax Pneumococcal 13-valent Conjugate Vaccine Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 75. Walvax Pneumococcal 13-valent Conjugate Vaccine Product Portfolio Table 76. Walvax Recent Development Table 77. Key Raw Materials Table 78. Raw Materials Key Suppliers Table 79. Pneumococcal 13-valent Conjugate Vaccine Distributors List Table 80. Pneumococcal 13-valent Conjugate Vaccine Customers List Table 81. Research Programs/Design for This Report Table 82. Authors List of This Report Table 83. Secondary Sources Table 84. Primary Sources List of Figures Figure 1. Pneumococcal 13-valent Conjugate Vaccine Product Image Figure 2. Global Pneumococcal 13-valent Conjugate Vaccine Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Pneumococcal 13-valent Conjugate Vaccine Market Size (2021-2032) & (US$ Million) Figure 4. Global Pneumococcal 13-valent Conjugate Vaccine Sales (2021-2032) & (K Units) Figure 5. Global Pneumococcal 13-valent Conjugate Vaccine Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Pneumococcal 13-valent Conjugate Vaccine Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. 0.5ml Image Figure 9. Other Image Figure 10. Global Pneumococcal 13-valent Conjugate Vaccine Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 11. Global Pneumococcal 13-valent Conjugate Vaccine Sales Market Share 2021 VS 2025 VS 2032 Figure 12. Global Pneumococcal 13-valent Conjugate Vaccine Sales Market Share by Type (2021-2032) Figure 13. Global Pneumococcal 13-valent Conjugate Vaccine Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 14. Global Pneumococcal 13-valent Conjugate Vaccine Revenue Market Share 2021 VS 2025 VS 2032 Figure 15. Global Pneumococcal 13-valent Conjugate Vaccine Revenue Market Share by Type (2021-2032) Figure 16. Hospital Image Figure 17. Clinic Image Figure 18. Global Pneumococcal 13-valent Conjugate Vaccine Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 19. Global Pneumococcal 13-valent Conjugate Vaccine Sales Market Share 2021 VS 2025 VS 2032 Figure 20. Global Pneumococcal 13-valent Conjugate Vaccine Sales Market Share by Application (2021-2032) Figure 21. Global Pneumococcal 13-valent Conjugate Vaccine Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 22. Global Pneumococcal 13-valent Conjugate Vaccine Revenue Market Share 2021 VS 2025 VS 2032 Figure 23. Global Pneumococcal 13-valent Conjugate Vaccine Revenue Market Share by Application (2021-2032) Figure 24. North America Pneumococcal 13-valent Conjugate Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 25. North America Pneumococcal 13-valent Conjugate Vaccine Sales Market Share by Country (2021-2032) Figure 26. U.S. Pneumococcal 13-valent Conjugate Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 27. Canada Pneumococcal 13-valent Conjugate Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 28. Mexico Pneumococcal 13-valent Conjugate Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 29. Europe Pneumococcal 13-valent Conjugate Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 30. Europe Pneumococcal 13-valent Conjugate Vaccine Sales Market Share by Country (2021-2032) Figure 31. Germany Pneumococcal 13-valent Conjugate Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 32. France Pneumococcal 13-valent Conjugate Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 33. U.K. Pneumococcal 13-valent Conjugate Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 34. Italy Pneumococcal 13-valent Conjugate Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 35. Netherlands Pneumococcal 13-valent Conjugate Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 36. Asia Pacific Pneumococcal 13-valent Conjugate Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 37. Asia Pacific Pneumococcal 13-valent Conjugate Vaccine Sales Market Share by Country (2021-2032) Figure 38. China Pneumococcal 13-valent Conjugate Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 39. Japan Pneumococcal 13-valent Conjugate Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 40. South Korea Pneumococcal 13-valent Conjugate Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 41. Southeast Asia Pneumococcal 13-valent Conjugate Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 42. India Pneumococcal 13-valent Conjugate Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 43. Australia Pneumococcal 13-valent Conjugate Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 44. South America, Middle East and Africa Pneumococcal 13-valent Conjugate Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 45. South America, Middle East and Africa Pneumococcal 13-valent Conjugate Vaccine Sales Market Share by Country (2021-2032) Figure 46. Brazil Pneumococcal 13-valent Conjugate Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 47. South Africa Pneumococcal 13-valent Conjugate Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 48. Saudi Arabia Pneumococcal 13-valent Conjugate Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 49. Turkey Pneumococcal 13-valent Conjugate Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 50. Argentina Pneumococcal 13-valent Conjugate Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 51. UAE Pneumococcal 13-valent Conjugate Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 52. Egypt Pneumococcal 13-valent Conjugate Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 53. Chile Pneumococcal 13-valent Conjugate Vaccine Sales and Growth Rate (2021-2032) & (K Units) Figure 54. Global Pneumococcal 13-valent Conjugate Vaccine Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 55. Global Pneumococcal 13-valent Conjugate Vaccine Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 56. North America Pneumococcal 13-valent Conjugate Vaccine Revenue (2021-2032) & (US$ Million) Figure 57. North America Pneumococcal 13-valent Conjugate Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 58. Europe Pneumococcal 13-valent Conjugate Vaccine Revenue (2021-2032) & (US$ Million) Figure 59. Europe Pneumococcal 13-valent Conjugate Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 60. Asia-Pacific Pneumococcal 13-valent Conjugate Vaccine Revenue (2021-2032) & (US$ Million) Figure 61. Asia-Pacific Pneumococcal 13-valent Conjugate Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 62. South America, Middle East and Africa Pneumococcal 13-valent Conjugate Vaccine Revenue (2021-2032) & (US$ Million) Figure 63. South America, Middle East and Africa Pneumococcal 13-valent Conjugate Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. Pneumococcal 13-valent Conjugate Vaccine Value Chain Figure 65. Manufacturing Cost Structure Figure 66. Pneumococcal 13-valent Conjugate Vaccine Production Mode & Process Figure 67. Direct Comparison with Distribution Share Figure 68. Distributors Profiles Figure 69. Years Considered Figure 70. Research Process Figure 71. Key Executives Interviewed

Scope & coverage.

Types
  • 0.5ml
  • Other
Applications
  • Hospital
  • Clinic
Companies covered
  • Pfizer
  • BIOKANGTAI
  • Walvax

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Pneumococcal 13-valent Conjugate Vaccine Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Pneumococcal 13-valent Conjugate Vaccine Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Pneumococcal 13-valent Conjugate Vaccine Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Pneumococcal 13-valent Conjugate Vaccine Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Pneumococcal 13-valent Conjugate Vaccine Market Dynamics
  1. 2.1 Pneumococcal 13-valent Conjugate Vaccine Industry Trends
  2. 2.2 Pneumococcal 13-valent Conjugate Vaccine Industry Drivers
  3. 2.3 Pneumococcal 13-valent Conjugate Vaccine Industry Opportunities and Challenges
  4. 2.4 Pneumococcal 13-valent Conjugate Vaccine Industry Restraints
3 Pneumococcal 13-valent Conjugate Vaccine Market by Manufacturers
  1. 3.1 Global Pneumococcal 13-valent Conjugate Vaccine Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Pneumococcal 13-valent Conjugate Vaccine Sales by Manufacturers (2021-2026)
  3. 3.3 Global Pneumococcal 13-valent Conjugate Vaccine Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Pneumococcal 13-valent Conjugate Vaccine Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Pneumococcal 13-valent Conjugate Vaccine Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Pneumococcal 13-valent Conjugate Vaccine Manufacturers, Product Type & Application
  7. 3.7 Global Pneumococcal 13-valent Conjugate Vaccine Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Pneumococcal 13-valent Conjugate Vaccine Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Pneumococcal 13-valent Conjugate Vaccine Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Pneumococcal 13-valent Conjugate Vaccine Tier 1, Tier 2, and Tier 3
4 Pneumococcal 13-valent Conjugate Vaccine Market by Type
  1. 4.1 Pneumococcal 13-valent Conjugate Vaccine Type Introduction
  2. 4.1.1 0.5ml
  3. 4.1.2 Other
  4. 4.2 Global Pneumococcal 13-valent Conjugate Vaccine Sales by Type
  5. 4.2.1 Global Pneumococcal 13-valent Conjugate Vaccine Sales by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Pneumococcal 13-valent Conjugate Vaccine Sales by Type (2021-2032)
  7. 4.2.3 Global Pneumococcal 13-valent Conjugate Vaccine Sales Market Share by Type (2021-2032)
  8. 4.3 Global Pneumococcal 13-valent Conjugate Vaccine Revenue by Type
  9. 4.3.1 Global Pneumococcal 13-valent Conjugate Vaccine Revenue by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Pneumococcal 13-valent Conjugate Vaccine Revenue by Type (2021-2032)
  11. 4.3.3 Global Pneumococcal 13-valent Conjugate Vaccine Revenue Market Share by Type (2021-2032)
5 Pneumococcal 13-valent Conjugate Vaccine Market by Application
  1. 5.1 Pneumococcal 13-valent Conjugate Vaccine Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.2 Global Pneumococcal 13-valent Conjugate Vaccine Sales by Application
  5. 5.2.1 Global Pneumococcal 13-valent Conjugate Vaccine Sales by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Pneumococcal 13-valent Conjugate Vaccine Sales by Application (2021-2032)
  7. 5.2.3 Global Pneumococcal 13-valent Conjugate Vaccine Sales Market Share by Application (2021-2032)
  8. 5.3 Global Pneumococcal 13-valent Conjugate Vaccine Revenue by Application
  9. 5.3.1 Global Pneumococcal 13-valent Conjugate Vaccine Revenue by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global Pneumococcal 13-valent Conjugate Vaccine Revenue by Application (2021-2032)
  11. 5.3.3 Global Pneumococcal 13-valent Conjugate Vaccine Revenue Market Share by Application (2021-2032)
6 Global Pneumococcal 13-valent Conjugate Vaccine Sales by Region
  1. 6.1 Global Pneumococcal 13-valent Conjugate Vaccine Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Pneumococcal 13-valent Conjugate Vaccine Sales by Region (2021-2032)
  3. 6.2.1 Global Pneumococcal 13-valent Conjugate Vaccine Sales by Region (2021-2026)
  4. 6.2.2 Global Pneumococcal 13-valent Conjugate Vaccine Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Pneumococcal 13-valent Conjugate Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Pneumococcal 13-valent Conjugate Vaccine Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Pneumococcal 13-valent Conjugate Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Pneumococcal 13-valent Conjugate Vaccine Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Pneumococcal 13-valent Conjugate Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Pneumococcal 13-valent Conjugate Vaccine Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Pneumococcal 13-valent Conjugate Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Pneumococcal 13-valent Conjugate Vaccine Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Pneumococcal 13-valent Conjugate Vaccine Revenue by Region
  1. 7.1 Global Pneumococcal 13-valent Conjugate Vaccine Revenue by Region
  2. 7.1.1 Global Pneumococcal 13-valent Conjugate Vaccine Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Pneumococcal 13-valent Conjugate Vaccine Revenue by Region (2021-2026)
  4. 7.1.3 Global Pneumococcal 13-valent Conjugate Vaccine Revenue by Region (2027-2032)
  5. 7.1.4 Global Pneumococcal 13-valent Conjugate Vaccine Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Pneumococcal 13-valent Conjugate Vaccine Revenue (2021-2032)
  8. 7.2.2 North America Pneumococcal 13-valent Conjugate Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Pneumococcal 13-valent Conjugate Vaccine Revenue (2021-2032)
  11. 7.3.2 Europe Pneumococcal 13-valent Conjugate Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Pneumococcal 13-valent Conjugate Vaccine Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Pneumococcal 13-valent Conjugate Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Pneumococcal 13-valent Conjugate Vaccine Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Pneumococcal 13-valent Conjugate Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Pfizer
  2. 8.1.1 Pfizer Company Information
  3. 8.1.2 Pfizer Business Overview
  4. 8.1.3 Pfizer Pneumococcal 13-valent Conjugate Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Pfizer Pneumococcal 13-valent Conjugate Vaccine Product Portfolio
  6. 8.1.5 Pfizer Recent Developments
  7. 8.2 BIOKANGTAI
  8. 8.2.1 BIOKANGTAI Company Information
  9. 8.2.2 BIOKANGTAI Business Overview
  10. 8.2.3 BIOKANGTAI Pneumococcal 13-valent Conjugate Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 BIOKANGTAI Pneumococcal 13-valent Conjugate Vaccine Product Portfolio
  12. 8.2.5 BIOKANGTAI Recent Developments
  13. 8.3 Walvax
  14. 8.3.1 Walvax Company Information
  15. 8.3.2 Walvax Business Overview
  16. 8.3.3 Walvax Pneumococcal 13-valent Conjugate Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Walvax Pneumococcal 13-valent Conjugate Vaccine Product Portfolio
  18. 8.3.5 Walvax Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Pneumococcal 13-valent Conjugate Vaccine Value Chain Analysis
  2. 9.1.1 Pneumococcal 13-valent Conjugate Vaccine Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Pneumococcal 13-valent Conjugate Vaccine Production Mode & Process
  6. 9.2 Pneumococcal 13-valent Conjugate Vaccine Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Pneumococcal 13-valent Conjugate Vaccine Distributors
  9. 9.2.3 Pneumococcal 13-valent Conjugate Vaccine Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst